The study for the effect of intravitreous injection of ranibizumab (product name: Lucentis) and subthreshold laser photocoagulation on diabetic macular edema

Phase 3

• Conditions: diabetic macular edema

• Registration Number: JPRN-UMIN000017037
• Lead Sponsor: Jichi Medica University, Saitama Medical Center

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2015-04-20
• Study Completion: 2017-03-31
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up complete
• Sex: All
• Target Recruitment: 100

Inclusion Criteria

Not provided

Exclusion Criteria

Patients who receive occular surgical treatments within 3 months Patients who receive other macular diseases

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
best-corrected visual acuity (before treatment, 3 months later, 6 months later, 12 months later) total number of injections (for 12 months) change in central retinal subfield thickness (3 months later, 6 months later, 12 months later)

Secondary Outcome Measures

Name	Time	Method
fluorescein angiography (before treatment, 3 months later, 6 months later, 12 months later)